Takeda NDAs In Asia Sign Of Progress In Reaching Outside of Main Markets
This article was originally published in PharmAsia News
Executive Summary
Progress in filing new drug applications across Asia shows the once squarely Japanese-focused firm is on a steady growth path in emerging markets in its own backyard. Takeda’s Oct. 5 acquisition of vaccine firm LigoCyte opens doors for new products.